6,087 reports of this reaction
4.3% of all INFLIXIMAB DYYB reports
#4 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #4 most commonly reported adverse reaction for INFLIXIMAB DYYB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 6,087 FDA adverse event reports linking INFLIXIMAB DYYB to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 4.3% of all 142,758 adverse event reports for this drug.
Patients taking INFLIXIMAB DYYB who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is moderately reported among INFLIXIMAB DYYB users, representing a notable but not dominant share of adverse events.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for INFLIXIMAB DYYB:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 6,087 FDA reports for INFLIXIMAB DYYB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 4.3% of all adverse event reports for INFLIXIMAB DYYB, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking INFLIXIMAB DYYB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.